Menu
Reference is made to the stock exchange announcement of Thor Medical ASA (the "Company") today regarding the completion of the annual general meeting. For the sake of good order, it is noted that a minor error has been detected in the minutes, where it was stated that the members of the nomination committee shall receive fees from taking office until the annual general meeting in 2024. This should be 2025, as suggested by the nomination committee and as resolved by the annual general meeting of the Company.
Attached are updated minutes to reflect the resolution made by the ordinary general meeting.
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
To learn more, visit www.thormedical.no.
